Select A Category

NSABP B-57-I/AFT – 05/ABCSG 42/BIG 14-03/PALbociclib CoLlaborative Adjuvant Study (PALLAS)

A Randomized Phase III Trial Of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone For Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Primary Objective: To compare invasive disease-free survival (iDFS) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer (EBC).

Patient Population: Hormone receptor +/HER2- invasive early breast cancer

Target Accrual: 4,600 patients

Status: Active, not recruiting 

ClinicalTrials.gov IdentifierNCT02513394